Drug Trial Radar · NCT06414460
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Apr 25, 2025
Primary completion
Mar 31, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- InSilico Medicine Hong Kong LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Conditions
- Locally Advanced/Metastatic Solid Tumors
Interventions
ISM3412Drug
ISM3412 will be administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT) eventsTime frame: 31 days
- Incidence and severity of adverse events (AEs)Time frame: Approximately 30 months
- Recommended phase 2 dose (RP2D)Time frame: Approximately 30 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
Smilow Cancer Hospital at Yale New Haven Breast Center
New Haven, Connecticut · Recruiting
Community Cancer Center North
Indianapolis, Indiana · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen university cancer center
Guangzhou, Guangdong, China · Recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
Shanghai Gobroad Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.